IDEC 10603--IDEC Y2B8 ADMINISTERED TO PATIENTS WITH B CELL LYMPHOMA

IDEC 10603--IDEC Y2B8 用于 B 细胞淋巴瘤患者

• 批准号: 6275302
• 负责人: Leo I. Gordon
• 金额: $ 2.26万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6275302
• 关键词: B lymphocyte; CD antigens; clinical research; clinical trial phase I; human subject; immunotherapy; monoclonal antibody

IDEC-Y2B8 (IDEC-103) is a murine IgG1 kappa monoclonal antibody and IDEC- C2B8 (IDEC-102) is a chimeric igG1 kappa monoclonal antibody, with mouse variable and human constant regions. Both antibodies recognize and show specificity for the CD20 antigen expressed on normal B cells and most malignant B-cell lymphomas. High-dose safety studies in cynomolgus monkeys have revealed no adverse clinical events with either antibody, and there were no significant abnormalities on laboratory tests or on histopathology.

IDEC-Y2B8 (IDEC-103) 是一种鼠 IgG1 kappa 单克隆抗体，IDEC- C2B8 (IDEC-102) 是一种嵌合 igG1 kappa 单克隆抗体，与小鼠 可变区和人类恒定区。两种抗体均能识别并显示 对正常 B 细胞和大多数细胞上表达的 CD20 抗原具有特异性 恶性 B 细胞淋巴瘤。食蟹猴高剂量安全性研究 已显示这两种抗体均未出现不良临床事件，并且 实验室检查或组织病理学未见明显异常。